1. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189–1199.
Article
2. Hodgson SF. Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am. 1990; 19:95–111.
Article
3. Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis. 2001; 60:521–522.
Article
4. Kim JW, Kim JJ, Lee HS, Choo SK, Oh HK, Chang JS. Low energy femur shaft and subtrochanteric fracture with bisphosphonate therapy. Korean J Bone Metab. 2010; 17:19–23.
5. Kiuru MJ, Pihlajamaki HK, Ahovuo JA. Fatigue stress injuries of the pelvic bones and proximal femur: evaluation with MR imaging. Eur Radiol. 2003; 13:605–611.
Article
6. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008; 39:224–231.
Article
7. Nawata H, Soen S, Takayanagi R, et al. Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis: Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005; 23:105–109.
Article
8. Yang KH, Sim DS. Clinical consideration on insufficiency fracture of femur. Korean J Bone Metab. 2009; 16:37–41.